

## DAFTAR PUSTAKA

1. World Health Organization (WHO) Global Tuberculosis Report 2012. Available from: [WWW.Who.int/tb/publications/global\\_report/2012/gtbr11\\_full.pdf](http://WWW.Who.int/tb/publications/global_report/2012/gtbr11_full.pdf). ( cited Mei 20<sup>th</sup> 2014).
2. Treatment of Tuberculosis Guidelines . WHO. Fourth edition. 2009.
3. Daley CL. Update in tuberculosis 2009. *Am J Respir Crit Care Med*. 2010; 181:550-555.
4. Ahmad S. Pathogenesis, immunology, and diagnosis of latent mycobacterium tuberculosis infection. *Clin Dev Immunol*. 2011; 2011:1-17.
5. Glickman MS, Jacobs WR. Microbial pathogenesis of mycobacterium tuberculosis: Dawn of a discipline. *Cell*. 2001 Feb; 104:477-485.
6. Maartens G, Wilkinson RJ. Tuberculosis. *The Lancet*. 2007 Dec; 370:2030-2043.
7. Kaufmann SHE. How can immunology contribute to the control of tuberculosis? *Nat Rev Immunol*. 2001 Oct; 1:20-29.
8. Raviglione MC, O'Brien RJ. Tuberculosis. In: Anthony S. Fauci, *et al*. Harrison's Principles of Internal Medicine. New York. *The McGraw-Hill Companies, Inc*; 2008; p.1006-1020.
9. Raja A. Immunology of tuberculosis. *Indian J Med Res*. 2004 Oct; 120:213-232.
10. Flynn JL, John C. Immunology of tuberculosis. *Annu Rev Immunol*. 2001; 19:93-129.
11. Schluger NW. The Pathogenesis of Tuberculosis. *Am J Respir Cell Mol Biol*. 2005; 32:251-256.
12. Van Crevel R, Ottenhoff THM, van der Meer JWM. Innate immunity to Mycobacterium tuberculosis. *Clin Microbiol Rev*. 2002 Apr; 15:294-309.
13. Saiga H, Shimada Y, Takeda K, et al. Innate immune effectors in mycobacterial infection. *Clin Dev Immunol*. 2011; 2011:1-8.
14. Liu PT, Modlin RL. Human macrophage host defense against Mycobacterium tuberculosis. *Curr Opinion Immunol*. 2008; 20:371-376.

15. Pieters J. Mycobacterium tuberculosis and the macrophage: Maintaining a balance. *Cell Host and Microbe*.2008; 3:399-407.
16. Kaufmann SHE. New issues in tuberculosis. *Ann Rheum Dis*. 2004; 63:50-56.
17. Iyonaga K, McCarthy KM, Schneeberger EE. Dendritic cells and the regulation of a granulomatous immune response in the lung. *Am J Respir Cell Mol Biol*.2002; 26:671-679.
18. Bottasso O, Bay ML, Besedovsky H, Del Rey A. The Immuno-endocrine component in the pathogenesis of tuberculosis. *Scand J Immunol*. 2007; 66:166-175.
19. Schwander S, Dheda K. Human lung immunity against Mycobacterium tuberculosis. *Am J Respir Crit Care Med*. 2011 Nov; 183:696-707.
20. Ellner JJ. Review: The immune response in human tuberculosis-implications for tuberculosis control. *J Infect Dis*. 1997; 176:1351-1359.
21. Dietrich J, Doherty TM. Interaction of mycobacterium tuberculosis with the host: consequences for vaccine development. *The Authors Journal Compilation*. 2009; 117:440-457.
22. Saunders BM, Britton WJ. Life and death in the granuloma: immunopathology of tuberculosis. *Immunol Cell Biol*. 2007; 85:103-111.
23. Perhimpunan Dokter Paru Indonesia. Tuberkulosis. Dalam : Tuberkulosis, Pedoman diagnosis dan penatalaksanaan di Indonesia. Jakarta, Balai penerbit FKUI. Jakarta. 2011; h 1-64.
24. Dannenberg AM, Rook GAW. Pathogenesis of pulmonary tuberculosis : an interplay of tissue-damaging and macrophage-activating immune responses-dual mechanism that control bacillary multiplication. In : bloom BR ed. *Tuberculosis. Pathogenesis, Protection and control*. Washington : ASM press. 1994, PP 495 – 483.
25. Kementrian Kesehatan RI. Pedoman Nasional Pelayanan kedokteran. *Tata Laksana Tuberkulosis*. 2009.
26. Harada . Tuberculosis sequelae : clinical aspect. *PubMed*. 2000 Dec; 05(12):831-8,2000.

27. Maria Lucia. Functional profile Of Patients With Tuberculosis Sequelae In A University Hospital. *J Bras Pneumol*. 2006;32(1):43-7.
28. Murr C, Widner B, Wirleitner B. Neopterin as a Marker For Immune System activation. *Current Drug Metabolism*.2011; vol 3, no 2.
29. Moses O, Ebenezer O. levels Of Oxidative metabolites, Antioxidant and Neopterin in Nigerian Pulmonary Tuberculosis patients. *Eur J Gen Med*. 2011;8(3):213-218.
30. Chandra I, Lalitha V. Serum Neopterin Levels In HIV patients With And Without TB. *Indian J Med Res* 121.April 2012; 133: 220-225.
31. Teyfik T, Handan A. Serum Interleukin-2 andNeopterin Levels As Useful Markers For Treatment Of Active Pulmonary Tuberculosis. *Tohoku J Exp. Med* .2012;209:321-328.
32. Hassan K, Abdel R. BAL Neopterin.*Chest*.March,2010;133: 141-148.

